Phillip Dinh

发表

Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.

John F. Flaherty, M. Buti, P. Marcellin, 2014, Journal of hepatology.

Statistical Challenges in the Analyses of Bone Mineral Density in Pediatric Populations

Phillip Dinh, 2015, Therapeutic innovation & regulatory science.

Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.

M. Manns, T. Berg, P. Marcellin, 2014, Journal of hepatology.

Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild‐type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF

K. Kitrinos, E. Gane, E. Svarovskaia, 2014, Journal of medical virology.

Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation

S. Pungpapong, T. Schiano, L. Teperman, 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.

A. Horban, E. Gane, J. McHutchison, 2014, Gastroenterology.

Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B.

P. Marcellin, Y. Kim, G. Foster, 2015, Journal of hepatology.

Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.

M. Buti, P. Marcellin, S. Lim, 2016, Gastroenterology.

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

P. Marcellin, A. Horban, K. Kitrinos, 2013, Hepatology.

Randomized, placebo‐controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B

P. Pang, M. Pawłowska, J. McHutchison, 2012, Hepatology.

Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.

Rohit Loomba, Jörg Petersen, Thomas Berg, 2016, Journal of hepatology.

Efficacy and safety of tenofovir DF (DF) in chronic hepatitis B virus infected patients with documented lamivudine resistance (LAM-R)

A. Horban, K. Kitrinos, E. Gane, 2012 .

Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate.

D. Ge, F. Zoulim, P. Hengen, 2015, Journal of hepatology.

Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials

M. Buti, P. Marcellin, S. Gordon, 2015, PloS one.

Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B

T. Therneau, W. Kim, M. Buti, 2015, Cancer.

Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years

M. Buti, P. Marcellin, H. Janssen, 2015, Hepatology International.

Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml)

M. Buti, P. Marcellin, A. Horban, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B

M. Washington, M. Buti, P. Marcellin, 2014, Digestive Diseases and Sciences.

O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)

M. Buti, P. Marcellin, R. Idilman, 2015 .

factors Associated with the Lack of Achievement of Normal Alt in Chronic Hepatitis B (chb) Patients Treated with Tenofovir Df (tdf) for up to 5 Years : 411

M. Buti, P. Marcellin, E. Gane, 2012 .

Analyzing Longitudinal Data from Glaucoma Trials

Phillip Dinh, 2022, Therapeutic Innovation & Regulatory Science.

Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant.

Sue-Jane Wang, I. Zineh, E. Unger, 2011, The Journal of clinical psychiatry.

744 TENOFOVIR DF (TDF) IS SAFE AND WELL TOLERATED IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH PRE-EXISTING MILD RENAL IMPAIRMENT

A. Horban, E. Gane, G. Subramanian, 2013 .

Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations

Suneel K. Gupta, Phillip Dinh, N. Modi, 2019, Clinical neuropharmacology.

43 LONG TERM TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY AND THE RISK OF HEPATOCELLULAR CARCINOMA

W. Kim, M. Buti, T. Berg, 2013 .

HBsAg Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2A in Chronic Hepatitis B: Long-Term Results of a Global Randomized Controlled Trial

M. Buti, P. Marcellin, R. Mehta, 2016 .

P0644 : HCC risk scores: Application of the CU-HCC, GAG-HCC and page-B scores to chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF)

W. Kim, M. Buti, T. Berg, 2015 .

Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India

S. Sarin, Samir R. Shah, A. Sood, 2016, Hepatology International.

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)

Phillip Dinh, Fenghe Lu, A. Chabi, 2021, Journal of glaucoma.

Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.

M. Buti, T. Asselah, P. Marcellin, 2016, Journal of hepatology.

Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.

John F. Flaherty, A. Horban, E. Gane, 2014, Gastroenterology.

K. Kitrinos, E. Gane, E. Svarovskaia, 2014, Journal of medical virology.